期刊文献+

老年急性白血病临床特点及个体化治疗分析

Clinical Features and Individual Therapy Analysis of Elderly Patients with Acute Leukemia
下载PDF
导出
摘要 目的对老年急性白血病的临床特点及个体化治疗进行分析。方法选取老年急性白血病患者80例,按照第一次诱导缓解中化疗药物的用量将患者分为标准或亚标准计量组(A组)和小剂量组(B组),对两组患者的治疗效果进行综合评价。结果A、B两组患者完全缓解(CR)率分别为22.5%和45.0%,总有效率分别为57.5%和80.0%,平均生存时间分别为(175.6±20.3)d和(203.9±29.4)d,平均骨髓抑制持续时间分别为(22.4±6.3)d和(12.5±4.6)d,以上差异均具有统计学意义(P<0.05);不良反应发生率分别为92.0%和88.0%,差异无统计学意义(P>0.05)。结论老年急性白血病患者对化疗的耐受性较差,早期的死亡率比较高,生存时间短,需要对患者实施个体化治疗。 Objective To explore the clinical features and analyze the individualized treatment of elderly patients with acute leukemia. Methods 80 cases of elderly patients with acute leukemia were selected and divided into standard or sub-standard measurement group (group A) and low-dose group (group B), based on the amount of first remission induction chemotherapy drugs. After treatment, the efficacies of two groups of were evaluated. Results Complete remission (CR) rates of the two groups were 22.5%and 45.0%;total efficacy was 57.5%and 80.0%, average survival time was (175.6±20.3) d and (203.9±29.4) d;average bone marrow suppression time was (22.4±6.3) d and (12.5 ± 4.6) d, with statistically significant difference (P 〈0.05). Adverse reactions rates were 92.0% and 88.0%, without statistically significant difference (P〉0.05). Conclusions For elderly patients with acute leukemia, tolerance of chemotherapy is poor, early mortality is high, and survival time is short, so elderly patient with acute leukemia should be given individualized treatment.
作者 黄玉平
出处 《临床医学工程》 2014年第8期1007-1008,共2页 Clinical Medicine & Engineering
关键词 老年急性白血病 临床特点 个体化治疗 Elderly patients with acute leukemia Clinical features Individualized treatment
  • 相关文献

参考文献8

二级参考文献87

  • 1徐健,蔡浩彦.老年白血病诊治应注意的问题[J].新医学,2004,35(7):393-394. 被引量:6
  • 2陆益,陆益线.参芪扶正注射液的药理作用和临床应用[J].时珍国医国药,2006,17(10):2083-2085. 被引量:66
  • 3张淑彩,耿丽萍,马淑卿,陈静.恶性血液病患者化疗后急性粒细胞缺乏症的护理[J].现代护理,2006,12(25):2421-2422. 被引量:3
  • 4陈智超,王红祥,游泳,李秋柏,吕建,邵菁,邹萍.参芪扶正注射液对急性髓系白血病患者树突状细胞作用的体外研究[J].临床内科杂志,2007,24(7):455-457. 被引量:6
  • 5林风茹,郭晓楠,任金海.恶性血液病诊治和疗效标准[M].2版.北京:人民军医出版社,2009:536-537.
  • 6Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leuke-mia: introduction//World Health Organization classification oftumours : pathology & genetics, tumours of haematopoietic andlymphoid tissues. Lyon, France: International Agency for Researchon Cancer, 2001 : 77-80.
  • 7Sudo K, Ema H, Morita Y, et al. Age-associated characteristics ofmurine hematopoietic stem cells. J Exp Med, 2000,192: 1273-1280.
  • 8Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloidleukemia : real world data on decision to treat and outcomes fromthe Swedish Acute Leukemia Registry. Blood,2009 , 113 :4179-4187.
  • 9Rees JK, Gray RG,Swirsky D, et al. Principal results of the Med-ical Research Council’s 8th acute myeloid leukemia trial. Lancet,1986, 2:1236-1241.
  • 10Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modi-fied by the cyclin-dependent kinase inhitior pl6INK4a. Nature,2006,443:421426.

共引文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部